

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No. : *See*, Schedule A attached herewith

Assignee : BESINS INTERNATIONAL-USA and LABORATOIRES
BESINS INTERNATIONAL (collectively "BESINS
HEALTHCARE INC.")

Customer No. : 11030

REVOCATION OF POWER OF ATTORNEY
WITH NEW POWER OF ATTORNEY
AND CHANGE OF CORRESPONDENCE ADDRESS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

BESINS INTERNATIONAL-USA and LABORATOIRES BESINS
INTERNATIONAL (collectively "BESINS HEALTHCARE INC."), the assignees of 50% of the
right, title, and interest in the applications identified in Schedule A, attached herewith, hereby
revoke all previous powers of attorney given in the applications identified in Schedule A.

BESINS INTERNATIONAL-USA, LABORATOIRES BESINS
INTERNATIONAL, and BESINS HEALTHCARE INC. hereby appoint the practitioners
associated with the Customer Number 11030 as attorneys to transact all business connected with
the applications identified in Schedule A.

Please change the correspondence address for the applications identified in
Schedule A to the address associated with Customer Number 11030. The address associated
with Customer Number 11030 for all future correspondence is:


Daniel J. Hulseberg
Baker Botts L.L.P.
30 Rockefeller Plaza
New York, New York 10112

Pursuant to an Agreement Regarding Certain Patent Matters ("the Agreement"), effective as of August 1, 2000, between UNIMED PHARMACEUTICALS, INC. (now UNIMED PHARMACEUTICALS, LLC.), BESINS INTERNATIONAL-USA, INC., and LABORATORIES BESINS INTERNATIONAL, SAS. (collectively referred to as the "Parties"), UNIMED PHARMACEUTICALS, INC. will diligently prosecute and maintain the applications identified in Schedule A using counsel of its choice.


Additionally, pursuant to the Agreement, and a subsequent Assignment to the Agreement, the applications listed on Schedule A are and shall be jointly owned by LABORATORIES BESINS INTERNATIONAL, SAS. and UNIMED PHARMACEUTICALS, INC., with LABORATORIES BESINS INTERNATIONAL, SAS., and UNIMED PHARMACEUTICALS, INC. each owning an undivided one-half interest in the same in all countries in which patent prosecution is pursued as mutually agreed by the Parties

A Statement Under 37 C.F.R. 3.73(b) is submitted herewith. The undersigned, whose title is supplied below, is authorized to act on behalf of the assignee.

Dated: 10 Nov 2010

By: 
Name: Thomas W. MacAllister
Title: Vice President
BESINS INTERNATIONAL-USA

Dated: 17 Nov 2010

By: 
Name: Leslie Grunfeld
Title: Managing Director
LABORATOIRES BESINS INTERNATIONAL